Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Filings indexed 217 across all filing types
Latest filing 2021-03-30 Director's Dealing
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2021-03-30 English
FORM 3
Director's Dealing
2021-03-30 English
FORM 3
Director's Dealing
2021-03-30 English
FORM 3
Director's Dealing
2021-03-30 English
TITCOMB 13G - GAIN THERAPEUTICS, INC.
Major Shareholding Notification
2021-03-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about the closing of an IPO, entry into a material definitive agreement (Underwriting Agreement), amendments to the Certificate of Incorporation and Bylaws, and related exhibits. There are no financial statements or detailed financial performance data presented, nor is this an earnings release or annual/interim report. The document primarily announces corporate governance changes and material agreements related to the IPO. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2021-03-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.